Compare GSK plc (GSK) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Monster Beverage Corp — how do they compare? GSK plc trades at $46.59 (market cap $91.88B), while Monster Beverage Corp trades at $43.64 (market cap $85.51B). The key difference: GSK plc and Monster Beverage Corp are close in size by market cap, and GSK plc pays a 3.9% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Monster Beverage Corp for 72 Days on average.
| GSK | MNST | |
|---|---|---|
Market Cap | $91.88B | $85.51B |
Volume | 7,730,529 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $49.97 |
52-Week Low | $43.24 | $33.16 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $111.88B | $83.81B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Monster Beverage (MNST) trades at $43.58, up 1.63% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net margin of 23.08% and zero long-term debt. Recent news highlights international sales growth of 35% in Q2 and a 1:2 stock split effective August 2026.
Outlook remains positive with a consensus price target of $98.22, implying significant upside, supported by international expansion and a debt-free balance sheet. Risks include competitive pressures, regulatory challenges in markets like India, and rich valuation multiples such as a P/E of 40.42. Analyst consensus is bullish with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
